Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02994459
Other study ID # 201610005
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date July 1, 2017
Est. completion date January 2027

Study information

Verified date March 2024
Source University of Missouri-Columbia
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

People who are obese often have insulin resistance (inability of insulin to properly control blood sugar) and high blood sugar. However, not all people with obesity have this problem. About one-third of people with obesity have normal sugar metabolism (the way your body uses sugar). Similarly, not all people who are lean are also metabolically healthy and a subset of people who are lean are referred to as metabolically abnormal lean (MAL) or metabolically obese lean because they have the abnormalities in glucose metabolism typically associated with obesity. The reasons why some people with obesity have a problem with blood sugar control and others do not are not entirely clear. It is thought that impaired muscle sugar uptake is the main problem related to high blood sugar in people with obesity. However, adipose tissue (fat tissue) also consumes a substantial amount of blood sugar. Therefore, it is unclear whether muscle or adipose tissue (fat tissue) are primarily responsible for altered blood sugar concentrations in persons with metabolically abnormal obesity (MAO) (those with insulin resistance), compared to those with metabolically normal (healthy) obesity (MNO), or whether "healthy" adipose tissue (fat tissue) expansion in MNO people compared with lean people provides a vessel for blood sugar removal that helps maintain normal blood sugar concentration. Accordingly, the investigators will determine the amount of sugar that is taken up by the body and in the cells of adipose tissue (fat tissue) and muscle by infusing labeled sugar into the blood and looking at its disappearance from blood and appearance in adipose tissue (fat tissue) and muscle. The investigators will also determine how well insulin, a hormone that controls blood sugar, turns on signals that stimulate sugar uptake in fat and muscle cells. These studies will be done after an overnight fast and during an infusion of sugar and insulin (hyperinsulinemic-euglycemic clamp), in sex- and age-matched people who are insulin resistant and insulin sensitive. People with obesity will also be invited to complete a ~10% diet-induced weight loss program and will be studied again after they have achieved the weight loss goal. A group of sex- and age-matched metabolically normal lean participants will serve as control group. An attempt will be made to also study a group of sex- and age-matched metabolically abnormal lean participants.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 90
Est. completion date January 2027
Est. primary completion date January 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria: All subjects - Age: greater than or equal to 18 years but <65 years - Weight stable (i.e., ±2 kg for at least 3 months) - Sedentary (less than 1 hour of structured exercise per week) - No evidence of significant organ system dysfunction or disease (e.g., diabetes, impaired kidney function, cancer, etc.) In addition, subjects must fulfill all of the following inclusion criteria. Metabolically Normal Lean - BMI greater than or equal to 18.5 but <25.0 kg/m2 - Fasting blood glucose: <100 mg/dl - Blood glucose 2 h after an OGTT: <140 mg/dl - HbA1c <5.7 %. Metabolically Normal Obese, likely insulin sensitive - BMI greater than or equal to 30.0 but <45.0 kg/m2 - Fasting blood glucose: <100 mg/dl - Fasting insulin: <20 mU/l - Blood glucose 2 h after an OGTT: <140 mg/dl - HbA1c <5.7 %. Metabolically Abnormal Obese, likely insulin resistant - BMI greater than or equal to 30.0 but <45.0 kg/m2 - Fasting blood glucose =100 mg/dl or blood glucose 2 h after an OGTT =140 mg/dl or fasting insulin >20 µU/mL or HbA1c >5.7 %. Metabolically Abnormal Lean - BMI greater than or equal to 18.5 but <25.0 kg/m2 - Fasting blood glucose =100 mg/dl or blood glucose 2 h after an OGTT =140 mg/dl or fasting insulin >20 µU/mL or HbA1c >5.7 %.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Weight Loss
Diet-induced weight loss (obese only)

Locations

Country Name City State
United States Washington University School of Medicine Saint Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
University of Missouri-Columbia

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Contribution of subcutaneous adipose tissue glucose uptake to whole-body glucose disposal in people who are insulin sensitive or insulin resistant (defined as insulin-mediated glucose disposal rate) Comparison of whole body and total adipose tissue glucose disposal rate assessed by using stable isotope labeled glucose tracer infusion in conjunction with dynamic PET imaging Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05081037 - Integrated Hyperglycaemia Incentivised Postnatal Surveillance Study (I-HIPS) N/A
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A
Active, not recruiting NCT05505994 - The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin Phase 3
Completed NCT03623139 - Effects of Basic Carbohydrate Counting Versus Standard Outpatient Nutritional Education in Type 2 Diabetes N/A
Completed NCT03623113 - The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes N/A
Completed NCT03359629 - Spectrophon LTD Glucometry Monitor Accuracy
Recruiting NCT03682640 - Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes Phase 2
Completed NCT02697305 - Incretin Effects of Branched Chain Amino Acids N/A
Completed NCT01737164 - Effect of Age on Glucose and Lipid Metabolism N/A
Terminated NCT00935766 - Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries Phase 3
Recruiting NCT03613688 - Effects of Deepure(Pu-erh Tea Extract) on Glycemic Control N/A
Completed NCT04098549 - The Effect of Rapid and Slow Glucose Fall on the Subsequent Glucose Production in People With Type 1 Diabetes N/A
Terminated NCT04031404 - Glucose and Non-Invasive Brain Stimulation N/A
Active, not recruiting NCT03577964 - Development of Pneumonia Due to Alveolar Glucose Levels in Systemic Hyperglycemia
Active, not recruiting NCT03232008 - Canderel:Effects on Blood Glucose Concentration and Appetite Scores N/A
Completed NCT04042142 - Glucagon Resistance in Patients With NAFLD N/A
Active, not recruiting NCT05607745 - Dietary Counseling Coupled With FMT in the Treatment of Obesity and NAFLD - the DIFTOB Study N/A
Completed NCT04004273 - Diabetes, Exercise and Liver Fat (DELIVER) N/A
Completed NCT04082923 - Effect of Meal Texture on Glucose-metabolism and Gut Hormone Response After Bariatric Surgery N/A